dr. shoushtari on the role of nivolumab and ipilimumab in mucosal melanoma
Published 3 years ago • 404 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
2:05
dr. shoushtari on the design of the checkmate-067 trial in advanced melanoma
-
1:18
dr. shoushtari on the data from the first-in-human trial for tebentafusp in advanced melanoma
-
1:22
dr. sznol discusses the combination of ipilimumab and nivolumab in melanoma
-
1:28
dr. jeffery s. weber on sequencing of nivolumab, ipilimumab in metastatic melanoma
-
2:11
dr. long on rationale for nivolumab/ipilimumab in patients with melanoma who have brain mets
-
1:25
dr. ott discusses ipilimumab and nivolumab in melanoma
-
1:33
dr. wolchok on the safety profile in checkmate-067 in melanoma
-
1:34
fda approves frontline nivolumab for advanced melanoma
-
3:16
melanoma patients who discontinued nivolumab and ipilimumab experienced equal or better pfs
-
1:00
dr. sznol on immune-related toxicities in melanoma
-
1:49
the significance of the ipilimumab/nivolumab findings in melanoma
-
1:59
checkmate 238: nivolumab versus ipilimumab in stage iii melanoma
-
0:53
dr. mario sznol describes nivolumab in advanced melanoma
-
0:57
dr. postow on os results of checkmate-069 study
-
6:19
should you treat melanoma with nivolumab and relatlimab (opdualag)?
-
1:22
first-in-human trial for tebentafusp in advanced melanoma shows promising safety profile
-
43:09
mucosal melanoma awareness facebook live
-
2:31
dr. wolchok on updated checkmate-067 results for melanoma
-
6:01
metastatic rcc: using frontline ipilimumab/nivolumab